Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates

Infant, Premature Clinical Trial

Official title:

Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02064712
• Other study ID #: NCPAPwean
• Status: Completed
• Phase: N/A
• Start date: September 2014
• Est. completion date: October 2018

Study information

• Verified date: October 2018
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine an optimal strategy to wean nasal continuous positive airway pressure (NCPAP) in preterm babies. The investigators hypothesize that babies that are taken off NCPAP at lower settings will need fewer total days on NCPAP than those babies taken off at higher settings.

Description:

This is a prospective randomized control trial to investigate an optimal method for discontinuing NCPAP therapy in preterm neonates. Neonates ≤32 weeks gestational age (GA) who require NCPAP in the delivery room or following extubation and are delivered in or transferred to Parkland Hospital Neonatal Intensive Care Unit (NICU) will be enrolled. The study team will approach the parents for verbal consent once neonates are stable on mechanical ventilation with a goal of extubation to NCPAP or once they are placed on initial NCPAP therapy. Neonates will be randomized to the high or low NCPAP arms and managed by their primary care team until they meet stability criteria as defined for a minimum of 12 hours. At that time they will be removed from NCPAP using two approaches: Group 1 will be decreased to 5cm H2O by the primary care team at which time NCPAP is removed if the neonate is clinically stable and the neonate placed in room air or on low-flow nasal cannula at ≤1L/min; Group 2 will be gradually weaned to a NCPAP of 3cm H2O at which time NCPAP is removed if the neonate is clinically stable for the prior 24 hours and the neonate placed in room air or on low-flow nasal cannula. Failure criteria will consist of clinical signs and laboratory results demonstrating the need for escalation of support, e.g., increasing apnea of prematurity (AOP) or need for increasing O2 supplementation. When a neonate has been stable for 5 days off NCPAP, they will complete the intervention arm of the study. All neonates will be followed until discharge, at which time the primary outcomes, e.g., days on NCPAP, duration of hospitalization and need for O2, will be determined for each group and compared. The calculated total sample size will require 238 neonates; i.e., 113 neonates per arm with a 5% drop-out rate will give a power of 0.80 and alpha value of 0.05 to detect a 25% difference in NCPAP days.

Stability Criteria:

1. NCPAP 5cm H2O

2. Supplemental oxygen <25% and not increasing

3. Respiratory rate ≤60 b/min

4. No significant respiratory distress, e.g., retractions, dyspnea

5. <3 episodes of apnea (>20 seconds) with bradycardia (<100 beats/min), and/or desaturations (<88%) within 1h or <5 episodes in prior 12h

6. Average oxygen saturation >87% with stable inspired O2

7. Tolerate time off NCPAP during routine care procedures

8. Neonates <27 wks GA must be ≥10d postnatal before weaning

Failure Criteria:

1. Occurrence of ≥3 apneas and/or bradycardia and/or desaturations within 1h or >4 episodes in a 12h period

2. Increasing need for supplemental O2 >30% to maintain O2 saturation >87%

3. Increase in the PaCO2 >65 mmHg

4. Increased work of breathing with respiratory rate >75 b/min for >2h

5. AOP requiring resuscitation

6. Initiation of nasal intermittent positive pressure ventilation (NIPPV) for respiratory support

Recruitment information / eligibility

• Status: Completed
• Enrollment: 226
• Est. completion date: October 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 32 Weeks

Eligibility

Inclusion Criteria:

• Neonates =32wks GA requiring NCPAP in the delivery room or NICU for increasing respiratory distress or post-extubation from mechanical ventilation.

Exclusion Criteria:

• Neonates requiring NCPAP for less than 48 hours

• Congenital anomalies

• Need for surgery

• Transfer to a different facility

• Grade 3-4 intraventricular hemorrhage

Related Conditions & MeSH terms

• Infant, Newborn
• Infant, Premature

Intervention

Other:
• Low CPAP Wean
Infants receive NCPAP by Hudson nasal prongs.
• High CPAP Wean
Infants receive NCPAP by Hudson nasal prongs.

Locations

Country	Name	City	State
United States	Parkland Memorial Hospital	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total days of NCPAP	Total number of days of CPAP therapy during the hospital stay	Until hospital discharge or 1 year of life
Secondary	Length of hospital stay	Number of days spent prior to being discharged from the hospital	Until hospital discharge or 1 year of life
Secondary	Duration of oxygen supplementation	Number of days	Until hospital discharge or 1 year of life